Bionics. vision by I'd like David. at Ekso you, start reiterating Thank our to here
our across are and about applications committed we industrial advanced medical mobility strength, motion and feel to robotics. great towards enhancing progress our And We with by endurance vision. human amplifying
the These higher by demand aspects continued the ability as of increasing XXXX results higher solid expansion driven the more growth an the all United States, Ekso in and across company. well second a revenue within quarter of EksoHealth primarily Ekso segment. for GT, margin the conversions GT of GT adoption results financial rate exoskeletons, for efficiently as reflected sales Our of our to Ekso demonstrate operate for rental-to-sale
we are While for with strategy we exoskeletons, optimized our our in commercial APAC. and gains very growth performance Ekso GT pleased were here from achieve the levels by U.S. softer EMEA offset our
year. million, margins points XXXX, revenue second from an Gross quarter increase $X.X XX%, million greater reducing our achieve same up of production approximately was costs. expanded XX while to selling to we quarter continue quarter Second $X.X in percentage as efficiencies of last the the from
quarters, several our on we've our better emphasized past the managing continued Over costs. focus
second structure to than for reduced have The net cash. quarter operating reduced we lower a leaner the pleased lower cost and with This prior of creating We quarter. year expenses XX% loss. XXXX achieved use operating a that organization our more enabled are are than that of our resulted us in efficiencies
which continue are their and our right we trend accomplishments, optimize this trending expect as patients. our direction. are We to of customers in to operational company proud of needs the our the meet we And
sales in XXXX, network traction primarily now beginning QX the business continued result and with U.S. me EksoHealth. by to the relative segments with for approximately Let our Revenue IDNs. higher quarter review XX% customers second increased of
rental bridge units. is customers an conversion also number important of purchase to pleased to our to from for We rental budgeted sales are see XX purchase. which their In of capital second customers a rates the offering our quarter, a increased existing
from is first This sales, rental as than customers. rentals quarter. United under XX% revenue to conversion States, revenue assuming up of well in the XX% booked new our the from all to upside deferred convert current rate two U.S. units more cumulative rental rental contract, million. we in $X as Additionally, brings Total that rental-to-sale rental
rehab As IRFs or serve we've prospects discussed across that markets. patient larger in the volumes many past, inpatient operate our customers many facilities of and multiple
strategy we resonating network clearly initial with opportunities Our have U.S. pilot with these is are commercial more seeing as started customers, several. and operators multi-unit with
opportunity. Additionally, has we care LTACs SNFs. including broader from the seeing our are term interest potential or within skilled also network of acute facilities This long and or segments, nursing expanding operators hospitals market
their optimistic partnership deliver this are ensure element closely larger engaged An with operators time. accelerate and a with important to us network GT in our includes them allows that revenue We working these over clinically will customers. larger programs both serving customers our on are And be Ekso of to focused these economically. more
now of own in top install centers the over includes base customers GTs. XX Our States, X and our XX% United the multiple rehabilitation of Ekso
device CCO, global progress traction his our increase commercialization as his Bill's customer and months technologies, our experienced ever three of our in May. than markets. customers of Bill we industry years line in confident Though top experience the sales announced than and and to and highly capabilities more medical of in and the accelerating ability leadership and responsible made to Ekso increased with our the XX continue knowledge in medical driving Officer, we management to in which industry Officer, I'm role global of key Chief as are team of sales We overseeing medical to his Bill revenues. Commercial more Shaw leader brings secure the to Commercial strategy, will addition In first these Chief intend company's for executional be adoption robotics a with Bionics. other leveraging pleased our
have last and benefits providers. addition provides team strategically appointment, and GT to and call, U.S. we strengthen already customer in our to we success on about achieved sales educating as that pipeline customers our patients expanded on Bill's In current mentioned potential the further the the to our care Ekso build
to our is hires. priorities up primary facilitate ramp team sales those recent of One of
full minimum continued units. drive we While revenue we volume, salesperson takes talent to of two a in growth achieve our for new sales for sales to the achieve we Ekso have our GT place believe and it objectives right typically believe quarters a
As I quarter performance market earlier, the EMEA APAC. softer in partially U.S. noted and in second growth by offset our was
Although in remain partners. to sales we transitioning that better achieved we made on these regions, process we disappointed model regions our to have ensure order channel distribution changes and supports the are on that a positioned targets capitalize tremendous to we have European In our of to not that these Organization confident that potential, to have potential. our are
awareness support and both to is better communicate equip APAC goal the provide in and expand channel the partners to shorten our near term cycle. Our EMEA customer our effectively sales products continue value to and to
a the protect, transform EksoHealth remain mobility. long deep While innovation can enhance Ekso and our we human company and and product, flagship to remains has history of and that developing further new committed GT our products technologies
intensity. range range extremity endurance of sessions upper commitment, EksoUE wearable this rehabilitation through the them have we upper expansion last device. a patients assist motion a to with extremity centers will portfolio dosage School wider and device the support provide and to of collaboration higher available by exoskeleton our provide rehabilitation developed for for the of Consistent EksoUE to impairments, and intend with EksoUE be was week, available The and and broad of our with the EksoUE Europe the United EksoUE, of The medical the announced we make and other increased who upper and a introduction aims of the made excellence believe its between wearable We University extremity generally Medicine. first Johns Ekso kind use. rehabilitation year. first of key this in Hopkins the the States to Bionics of placements, is end a
the about solutions for patients of developing remain with rehab from innovation excited planned product the and latest are look future. and spinal this exoskeleton to additional We launches macrobiotics in forefront at injury
We've WISE also in our study. made progress
of scope previously, get we we we so in in XXXX that As results could announced the study reduce XXXX. the
are pleased QX. announce and data in expect complete We the have their the that initial protocols, analysis to final we treatment completed patients to
benefits changes a from that customer we the and continued reduction, enable product received better order will benefits noticeable revenues We're deliver across using by primarily are their us to compared and provides. the validate business to Turning compelling of in EksoWorks to which industries. segment, offerings the with and receiving, to the product The believe and period timing also are grow automotive customers opportunities feedback EksoWorks and beyond productivity needs. industrial we our same continues a ago, this evaluation sectors Despite programs. lower EksoWorks due the to the there pleased are safety and verticals were year pilot evaluations evolve to we meet variety our exploring aviation with products customers
opening my concludes remarks. That
quarter second Now review over to I will financial to XXXX call Jack our results. Glenn the turn
